Accuray and Samsung NeuroLogica Collaborate on Imaging Tech

Accuray Incorporated has announced a partnership with Samsung HME America, Inc., also known as Samsung NeuroLogica, to develop advanced volumetric imaging capabilities for the CyberKnife® System. This collaboration was revealed during the American Society of Radiation Oncology (ASTRO) Annual Meeting in Boston, highlighting the importance of imaging in radiation therapy.

The partnership seeks to combine Samsung NeuroLogica's expertise in mobile computed tomography (CT) and volumetric imaging with Accuray's precision treatment delivery and robotic radiosurgery capabilities. Accuray has identified enhanced imaging as a priority for improving treatment efficiency and supporting clinical decision-making.

According to Steve La Neve, President and CEO of Accuray, the collaboration reflects a strategic approach to innovation, emphasizing the need to translate customer priorities into actionable solutions. The integration of Samsung's imaging technology is expected to provide clinicians with better visualization of patient anatomy during treatment.

Clinicians have expressed that volumetric imaging could significantly improve the treatment environment by allowing for simultaneous visualization of the target and surrounding anatomy. This capability may lead to more informed treatment decisions and adapt therapies based on real-time patient conditions.

The Royal Marsden NHS Foundation Trust has been selected as the first center to participate in this collaboration, exploring the potential of Samsung's volumetric imaging technology in robotic radiosurgery. Professor Nicholas van As, a consultant clinical oncologist at The Royal Marsden, noted the importance of this technology for adapting treatments to patient-specific anatomy.

As the collaboration progresses, Accuray and Samsung NeuroLogica will evaluate technical, clinical, and commercial opportunities, although no specific product offerings have been announced yet. The companies aim to ensure that any developments meet the stringent regulatory requirements of radiation oncology.

This partnership is part of Accuray's broader strategy to accelerate innovation and improve the efficacy of radiation therapy, demonstrating the company's commitment to enhancing the capabilities available to clinicians in the field.

Have news to announce?

Get your launch, funding round, or partnership covered on GAX Online, in front of tech buyers and the AI answer engines that cite us.